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Background: Breast cancer is attributable to modifiable risk factors including the intake of dietary n-3 polyunsaturated
fatty acids (PUFA). A key piece of evidence, yet to be addressed, that would demonstrate a causal relationship
between n-3 PUFA and breast cancer, is a dose-dependent effect of n-3 PUFA on tumour outcomes. Thus, the
objective of the present study was to determine whether n-3 PUFA reduces mammary gland tumor outcomes in a
dose-dependent manner in female MMTV-neu(ndl)-YD5 transgenic mice, an aggressive model of human breast
cancer.
Methods: Harems were provided one of three experimental diets comprised of 0, 3 or 9% (w/w) menhaden fish
oil containing n-3 PUFA. Female offspring were weaned onto the same parental diet and maintained on their
respective diet for 20 weeks. Tumour onset, size and multiplicity were measured throughout the study. Fatty acid
composition of mammary gland and tumours were determined by gas–liquid chromatography.
Results: Tumour size was significantly (p < 0.05) reduced in a dose-dependent manner. n-3 PUFA were also
incorporated in a dose-dependent manner; differential incorporation was observed for eicosapentaenoic and
docosapentaenoic acids into mammary gland tissue, while docosahexaenoic acid was preferentially incorporated
into tumours.
Conclusion: Overall, the present study provides fundamental knowledge about the dose-dependent effect of n-3
PUFA on tumour outcomes in a pre-clinical model and also sheds light on the differential role of individual n-3
PUFA on tumour outcomes.
Keywords: n-3 PUFA, Eicosapentaenoic acid, Docosahexaenoic acid, Mammary gland, MMTV-neu mice, Breast
cancer, Tumour, Tumour multiplicity, Tumour volume, PhospholipidsBackground
Breast cancer is more prevalent in Western countries,
including Canada (2012 incidence rate was 99 in 100,
000 people) [1], than in Asian countries, such as Japan
(2012 incidence rate was 44 in 100, 000 people) [2].
However, the difference in incidence rates between
Western and Asian societies is diminished when Asian* Correspondence: davidma@uoguelph.ca
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unless otherwise stated.populations migrate to Western countries [3,4]. This
suggests that environmental factors, including diet, may
play a role in breast cancer development. The intake of
n-3 polyunsaturated fatty acids (PUFA), which is high in
Asian diets and low in Western diets, has been shown to
be inversely correlated with breast cancer incidence
[5-8], while n-6 PUFA consumption, high in Western di-
ets, is associated with breast cancer incidence [4]. Recent
reviews and meta-analyses support a role for n-3 PUFA
in breast cancer prevention [9,10].
In rodent and in vitro models, n-3 PUFA have been
shown to reduce neoplastic growths [11-15]. Previously,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain






















Figure 1 The average tumour latency of mice fed a 0% (n = 16),
3% (n = 10) and 9% (n = 11) n-3 PUFA diet. No significant difference
existed between groups as determined by a one-way ANOVA.
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n-3 PUFA using the MMTV-neu(ndl)-YD5 mouse model.
Intake of a 3% weight/weight (w/w) menhaden fish oil
based diet reduced tumour volume and burden by ~30%
in comparison to mice receiving a 10% (w/w) n-6 PUFA
diet [14]. The MMTV-neu(ndl)-YD5 mouse model
over-expresses the neu oncogene which is homologous
with the human epidermal growth factor receptor 2
(HER2) gene found in humans. The over-expression of
HER2 is estimated to be responsible for 20-25% of human
breast cancer cases [15-17]. The incorporation of n-3
PUFA into cellular and tumour lipids is hypothesized
to be an important mechanism by which n-3 PUFA
elicit their anti-tumourigenic effects [13,18-20]. Other
mechanisms include the competitive inhibition of ara-
chidonic acid derived eicosanoids and the alteration of
lipid rafts [21].
While previous studies have shown that consuming
n-3 PUFA at a single dose has the ability to reduce
tumour growth [14,18], to the best of our knowledge
no one has investigated the dose-dependent effect of
n-3 PUFA in experimental rodent models. This funda-
mental knowledge is lacking and highly important for
substantiating the cause-effect relationship between n-
3 PUFA exposure and breast cancer outcomes. Thus,
the present study examined the effect of increasing
levels of n-3 PUFA, 0%, 3% and 9% (w/w), on tumour
onset, size, multiplicity and the incorporation of n-3
PUFA into phospholipids of tumours and their adjacent
mammary glands using MMTV-neu(ndl)-YD5 mice.
Results
Body growth and puberty onset
Final body weights of mice on the 0% n-3 PUFA diet
(27.6 ± 0.6 g) were not significantly different than those
of mice fed a 9% n-3 PUFA diet (28.7 ± 0.7 g). However,
mice fed either of the aforementioned diets had a signifi-
cantly smaller final body weight than mice fed the 3% n-3
PUFA diet (31.8 ± 0.8 g, p < 0.05). Puberty onset was sig-
nificantly (p < 0.05) delayed in mice fed either the 3%
(30.6 ± 1.7 days) or 9% (30.1 ± 0.4) n-3 PUFA diets com-
pared to mice fed the 0% n-3 PUFA diet (27.6 ± 0.5).
Tumour latency and tumour free status
Tumour latency was not significantly different between
the 3 groups, but average tumour latency, defined as the
average age at which the first tumour was identified, was
delayed in mice fed both 3% n-3 PUFA (108.7 ± 4.1 days)
and 9% n-3 PUFA (115.6 ± 3.9 days) relative to 0% n-3
PUFA (106.5 ± 3.2 days) fed mice (p = 0.21) (Figure 1).
The median age at which tumours were palpable (T50)
for the groups fed either the 0% or the 3% n-3 PUFA diets
was 104 days, while the T50 for the group fed a 9% n-3
PUFA diet was 110.5 days (Figure 2).Tumour multiplicity
Repeated measures analysis demonstrated that mice fed
the 9% n-3 PUFA diet had significantly reduced tumour
multiplicity in comparison to mice fed either the 0% or
3% n-3 PUFA diet, beginning on days 115 and 122, re-
spectively (p < 0.05) (Figure 3). This difference was main-
tained until the end of the study at 140 days. Final
tumour multiplicity was reduced by 12% and 40% in the
3% and 9% n-3 PUFA fed mice, respectively, relative to
the 0% n-3 PUFA fed controls.
Tumour volume
Repeated measures analysis demonstrated that average
tumour volume began to diverge significantly at 117 and
120 days of age for mice fed a 9% n-3 PUFA diet in com-
parison to mice fed a 0% n-3 PUFA diet as well as a 3%
n-3 PUFA diet, respectively (p < 0.05). While mice fed a
3% n-3 PUFA diet had significantly reduced average
tumour volume by day 133 in contrast to mice fed the
0% n-3 PUFA diet (p < 0.05) (Figure 4). Final tumour
volume was ~35% and 70% lower in the 9% n-3 PUFA
fed mice relative to the 3% and 0% n-3 PUFA fed mice,
respectively.
Mammary gland phospholipid composition
The incorporation of n-3 PUFA into PC within the
mammary gland was assessed to determine if the ob-
served effects were due to altered fatty acid composition
of the plasma membrane (Table 1). Compared to mice
fed the 0% n-3 PUFA diet (n = 5), there was preferential
incorporation of eicosapentaenoic acid (EPA, 20:5 n-3)
and docosapentaenoic acid (DPA, 22:5 n-3) in mice fed a
3% n-3 PUFA diet and further elevated in mice fed a 9%
n-3 PUFA diet (p < 0.05). Correspondingly, there was a
significant (p < 0.05) dose-dependent decrease in arachi-
donic acid (AA, 20:4 n-6). The n-6:n-3 PUFA ratio also
significantly decreased (p < 0.05) from 23.8 ± 8.5 in mice





































Figure 2 The proportion of mice tumour free throughout the duration of the study fed a 0% n-3 PUFA diet (n = 16), 3% n-3 PUFA diet
(n = 10), and 9% n-3 PUFA diet (n = 11). More mice remained tumour free longer in 3% and 9% n-3 PUFA fed mice.
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fatty acids (SFA) within PC was significantly reduced
(p < 0.05) in mice fed either a 3% or 9% n-3 PUFA diet
(respectively, 0.6 ± 0.04 and 0.5 ± 0.05) in comparison
to mice fed the 0% n-3 PUFA diet (1.0 ± 01). Similar effects
were observed in the PE fraction (data not shown).
Tumour phospholipid content
There were significant differences in the fatty acid com-
position of the tumor PC fraction between groups (n = 5
for mice fed either the 0% or the 3% n-3 PUFA diet, n = 4
for mice fed the 9% n-3 PUFA diet) (Table 2). A significant
(p < 0.05) dose-dependent reduction was observed for
linoleic acid (LA, 18:2 n-6) and AA in tumours of mice
fed increasing levels of n-3 PUFA in comparison to
mice fed 0% n-3 PUFA (p < 0.05). There was also a
dose-dependent increase in EPA accumulation into tu-
mours of mice fed increasing levels of n-3 PUFA in
comparison to mice fed 0% n-3 PUFA (p < 0.05). DHA
accumulation was only significantly greater in mice fed
the 9% n-3 PUFA diet in comparison to mice fed 0% n-3Figure 3 The average number of tumours palpitated per dietary inter
PUFA diet (n = 16), 3% n-3 PUFA diet (n = 10), and 9% n-3 PUFA diet
significant reduction in tumour multiplicity in comparison to mice fed eith
(p < 0.05).PUFA (p < 0.05). A significant dose-dependent reduction
(p < 0.05) in tumour n-6:n-3 PUFA ratio was observed
in both the 3% and 9% n-3 PUFA diets (9.5 ± 1.1 and
1.7 ± 0.1, respectively) in comparison to mice fed the 0%
n-3 PUFA diet (24.6 ± 6.8). The ratio of PUFA: SFA was
observed to be significantly reduced (p < 0.05) in mice
fed a 9% n-3 PUFA diet (0.5 ± 0.03) compared to mice
fed the 0% n-3 PUFA diet (0.87 ± 0.17). Similar effects
were observed in the PE, PS and PI fractions (data not
shown).
Discussion
The present study addresses a fundamental question of
causality by examining the dose response effect of n-3
PUFA on tumour outcomes in a pre-clinical model of
breast cancer. Epidemiological studies to date only pro-
vide correlative evidence in support of a beneficial effect
of n-3 PUFA in reducing the risk of developing breast
cancer [10]. Thus, a major gap remaining is demonstrating
a cause-effect relationship in human or preclinical models
[22]. To the best of our knowledge a fundamental dose-*
vention throughout the course of the study in mice fed a 0% n-3
(n = 11). The asterisk indicates that mice fed a 9% n-3 PUFA diet had a
er of the other diets as determined by a repeated measures analysis
CB
A
Figure 4 The average tumour volume per dietary intervention over the duration of the study in mice fed a 0% n-3 PUFA diet (n = 16),
3% n-3 PUFA diet (n = 10), and 9% n-3 PUFA diet (n = 11). Groups with a different letter indicate significantly different tumour volumes as
determined by a repeated measures analysis (p < 0.05).
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been previously reported. Thus, it is unknown whether ef-
fects at higher doses plateau or potentially cause harm.
The results of this study provide evidence that the intake
of n-3 PUFA, in a dose dependent manner results in a cor-
responding increase in n-3 PUFA in tumour phospholipids
associated with a reduction in tumour outcomes.
A key attribute of cause-effect relationships is demon-
strating dose dependency. Multiple parameters in this
study suggest a beneficial dose-dependent relationship
across the 0%, 3% and 9% (w/w) levels of n-3 PUFA andTable 1 Fatty acid composition of the







LA (18:2n-6) 30.8 ± 2.1a 20.9 ± 2.3b 11.9 ± 1.6c
AA (20:4n-6) 8.3 ± 0.5a 3.8 ± 0.2b 7.9 ± 2.1ab
DPA (22:5n-6) 0.8 ± 0.1a traceb traceb
ALA (18:3n-3) tracea tracea tracea
EPA (20:5n-3) tracea 0.7 ± 0.1b 4.0 ± 0.8c
DPA (22:5n-3) tracea 0.3 ± 0.4ab 1.9 ± 0.9b
DHA (22:6n-3) tracea tracea tracea
Total n-6 41.4 ± 1.7a 25.2 ± 2.1b 20.3 ± 1.2c
Total n-3 0.03 ± 0.03a 1.1 ± 0.5b 6.0 ± 1.5c
n-6/n-3 ratio 1292.3a 23.8 ± 8.5b 3.4 ± 1.0c
Total SFA 43.6 ± 1.1a 45.9 ± 0.4ab 52.6 ± 0.9b
Total MUFA 14.1 ± 1.7a 23.4 ± 2.0a 21.0 ± 1.9b
Total PUFA 41.7 ± 1.3a 26.4 ± 2.6b 26.4 ± 1.4c
P/S Ratio 1.0 ± 0.1a 0.6 ± 0.04b 0.5 ± 0.05c
n = 4 for the 3% n-3 PUFA diet, n = 5 for both the 0% n-3 and 9% n-3 PUFA
dietary interventions. Values in the same row not sharing the same superscript
are significantly different from one another as determined by a one-way
ANOVA (p < 0.05).tumour outcomes. On average, tumour latency was de-
layed by 2% and 9% in mice fed 3% and 9% n-3 PUFA
diets, respectively (Figure 1). On average, the majority of
mice were tumour free longer throughout the later time
points in the 3% and 9% n-3 PUFA fed groups when
compared to the 0% n-3 PUFA fed group (Figure 2).
Tumour multiplicity was significantly (p < 0.05) decreased
at the highest dose of 9% n-3 PUFA (Figure 3). Tumour
volume was significantly (p < 0.05) and dose-dependently
decreased at all levels of treatment (Figure 4).
The current study showed a greater reduction in final
tumour volume in mice fed a 9% n-3 PUFA diet in com-






LA (18:2n-6) 10.1 ± 1.2a 13.9 ± 0.4b 5.1 ± 0.4c
AA (20:4n-6) 16.5 ± 1.3a 10.9 ± 0.6b 6.2 ± 0.3c
DPA (22:5n-6) 0.9 ± 0.2a 0.03 ± 0.02b 0.1 ± 0.1b
ALA (18:3n-3) 0.1 ± 0.1a 0a 0.01 ± 0.01a
EPA (20:5n-3) 0.1 ± 0.1a 0.8 ± 0.1b 3.1 ± 0.2c
DPA (22:5n-3) 0.2 ± 0.04a 0.8 ± 0.1b 1.3 ± 0.6ab
DHA (22:6n-3) 1.0 ± 0.2a 1.5 ± 0.3a 2.7 ± 0.2b
Total n-6 33.0 ± 2.3a 28.4 ± 0.6a 12.5 ± 0.9b
Total n-3 1.3 ± 0.3a 3.0 ± 0.3b 7.2 ± 0.4c
n-6/n-3 ratio 24.6 ± 6.8a 9.5 ± 1.1b 1.7 ± 0.1c
Total SFA 39.3 ± 1.3a 41.5 ± 0.4a 42.1 ± 0.9a
Total MUFA 26.4 ± 2.2a 26.2 ± 0.7a 38.1 ± 1.0b
Total PUFA 34.3 ± 3.3a 31.4 ± 0.7a 19.7 ± 0.6b
P/S Ratio 0.9 ± 0.2a 0.8 ± 0.03a 0.5 ± 0.03b
n = 4 for the 9% n-3 PUFA diet, n = 5 for both the 0% n-3 and 3% n-3 PUFA diets.
Values in the same row not sharing the same superscript are significantly different
from one another as determined by a one-way ANOVA (p < 0.05).
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(w/w) corn oil diet (enriched in n-6 PUFA) or a 10%
(w/w) menhaden fish oil diet beginning at 7–8 weeks
of age for the duration of a 61 week study [15]. The
study utilized the MMTV-neu mouse model, a less ag-
gressive model than the one utilized in the current
study. These investigators showed that a diet supplying
22.5% of total energy (10% w/w) from menhaden oil re-
sulted in a 30% reduction in tumour volume [15]. In
contrast, a similar amount of energy provided by life-
long exposure to a 9% n-3 PUFA diet in the present
study resulted in a 70% reduction in final tumour volume.
These observations suggest a potential benefit of long
term exposure to n-3 PUFA from conception through in
utero development, lactation, weaning, puberty and adult-
hood confers added protection against mammary tumour
development. This is supported by previous studies dem-
onstrating that the timing of exposure may influence
future cancer risk [11,23].
In regards to physiological relevance, the 9% n-3 PUFA
diet provided mice with 22% of total calories from fat,
but of greater relevance this diet provides 6.7% of the
total daily energy requirements from EPA and DHA, or
the equivalent of 11 g/day in humans (assuming the aver-
age human female consumes 2000 kcal/day). In humans
the consumption of 267 g of fish per day will provide ap-
proximately 11 g of EPA and DHA, or alternatively the
equivalent of 3 servings of an average 85 g salmon steak
[24]. While the intake of 11 g of EPA and DHA per day
may seem unrealistic, a study of 48 women demonstrated
that intake of up to 9 capsules of marine based n-3 PUFA,
providing up to 7.56 g of DHA+ EPA a day, for 6 months
was well tolerated by participants [25]. The prescribed
dosages produced similar levels of compliance among par-
ticipants and a dose response accumulation of EPA and
DHA was observed in serum and breast adipose tissue
[25]. In contrast, the equivalent quantity of EPA and DHA
from the 3% n-3 PUFA diet is achievable in humans
through the consumption of 3.4 g of EPA/DHA a day. Al-
ternatively, the balance of n-6 to n-3 PUFA is another way
to characterize the physiological relevance of the diets
used in the present study. In Australia, the ratio of n-6 to
n-3 PUFA in an individual’s diet ranges from 2 to 80,
which is similar to the variance of this ratio used in the
present study [26].
The anti-tumourigenic properties of n-3 PUFA are
largely related to their ability to incorporate into the
plasma membrane of target tissues and alter membrane-
protein and subsequently protein-protein interactions
[20]. The observed dose-dependent effects of a reduced
n6:n-3 PUFA dietary intake were associated with a dose-
dependent change in the fatty acid profile reflected in a
decreased n-6:n-3 PUFA ratio, driven by increases in n-3
PUFA, mainly EPA, DPA and DHA, and a concomitantdecrease in the n-6 PUFA, AA. These direct measure-
ments importantly confirm that the bioactive compo-
nents of the diet, n-3 and n-6 PUFA, are targeted to the
mammary gland and tumour of interest, which coin-
cided with reductions in tumour burden observed in the
mice. Marine-based oils contain multiple n-3 PUFA, but
the field has focused primarily on the study of EPA and
DHA. However, the present study observed significant
and appreciable incorporation of another n-3 PUFA,
docosapentaenoic acid (DPA, 22:5 n-3) (Table 2). The
biological role of DPA is not known, but one previous
study noted a similar observation [27]. Thus, DPA de-
serves more attention in future studies regarding cancer.
This is highly relevant given that DHA was only prefer-
entially incorporated into tumour phospholipids but not
into mammary gland phospholipids (Tables 1 and 2).
While speculative, these observations suggest differential
role of individual n-3 PUFA along the cancer trajectory.
Further research is required to better define the inter-
play between individual and combinations of n-3 PUFA
on tumour outcomes.
The present study did not examine mechanisms of ac-
tion, but the change in membrane fatty acid composition
is important as n-6 and n-3 PUFA compete for the same
eicosanoid enzymes. The observed anti-tumourigenic
effects of the diets utilized in this study may be due to a
dose-dependent increase in n-3 PUFA consumption, a
dose-dependent reduction in n-6 PUFA intake or a com-
bination of the two with a dose-dependent reduction in
the n-6:n-3 PUFA dietary ratio. Prostaglandins, leukotri-
enes and thromboxanes derived from AA promote inflam-
mation and cellular proliferation; however, when they are
derived from n-3 PUFA they promote apoptosis and in-
hibit cell proliferation [28]. Additionally, n-3 PUFA have
been found to elevate pro-apoptotic factors including
caspases 9 and 3, Bcl2, and reactive oxygen species,
while also reducing DNA synthesis, cellular prolifera-
tion and the integration of growth factor receptors into
the plasma membrane [18,19]. Changes in membrane
composition were observed in both mammary and tumour
tissue, but it is likely that the change in tumour compos-
ition is most relevant in explaining the anti-tumourigenic
effects of n-3 PUFA. The control diet utilized in this study
contained 10% (w/w) safflower oil which is abundant in
LA and scarce in other n-6 PUFA. The n-6 and n-3
families of fatty acids refer to many structurally similar
molecules which may have different biological effects.
Thus, in this study, we can only conclude that in compari-
son to an LA rich diet, a fish oil diet rich in EPA and
DHA is protective against tumour development.
Pubertal onset has been linked to breast cancer as earlier
menarches place females at a greater risk for breast cancer
[29]. In the present study, the onset of puberty in the mice
was significantly (p < 0.05) delayed by ~3 days in mice fed
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n-3 PUFA fed mice. Mechanistically, n-3 PUFA may in-
fluence circulating estrogen levels, a key regulator of
puberty [11]. This observation suggests further investi-
gation on the role of n-3 PUFA in regulating hormonal
influences on puberty and cancer. Furthermore, this ob-
servation supports growing evidence that critical periods
of early development such as puberty have important
influences on future cancer risk [23,30,31].
In conclusion, the present study contributes import-
antly to addressing an important gap in our fundamental
understanding of the causal role for n-3 PUFA in breast
cancer prevention.
Methods
Animals, diets and genotyping
Mice were housed in ventilated cages in a humidity and
temperature controlled environment on a 12 hour light-
12 hour dark cycle for the duration of the study. MMTV-
neu(ndl)-YD5 mice on an FVB background were obtained
from Dr. William Muller at the University of McGill.
Harems consisted of one male heterozygous MMTV-neu
(ndl)-YD5 mouse and three female FVB mice yielding pro-
geny with a wildtype or a heterozygous genotype. Harems
were fed a modified AIN93G diet (Research Diets Inc.) ad
libitum containing 10% fat (w/w) providing 22% of the
mouse’s total daily energy requirements. Mice received di-
ets containing n-3 PUFA with different amounts (% w/w)
of menhaden fish oil. Diets comprised either 0% n-3 PUFA
(10% w/w safflower oil (rich in n-6 PUFA), n = 16); 3% n-3
PUFA (7% safflower oil and 3% menhaden oil, n = 10);
or 9% n-3 PUFA (1% safflower oil and 9% menhaden oil,
n = 11). The group receiving a diet containing 0% n-3
PUFA were used as a control as this is representative of
a typical n-6 PUFA enriched, Western style diet. Off-
spring were weaned at 3 weeks of age and genotyped as
described previously [14]. Female MMTV-neu(ndl)-YD5
transgenic offspring were maintained on their parental
diet while males and wildtype females were euthanized
post-weaning. Thus, female offspring received the same
diet throughout life, from in utero until termination at
20 weeks of age. All experimental procedures were
approved by the institutional animal care committee
(University of Guelph).
Phenotypic measurements
Post-weaning, female mice were checked daily for vaginal
opening to determine the onset of puberty. The body
weights of mice were measured weekly from 3 to 20 weeks
of age on an electronic scale. Beginning at week 12, mice
were palpated three times a week to detect the presence of
new mammary gland tumour formations. When a tumour
was detected, biweekly measurements were taken for the
duration of the study. Tumours were measured along thesagittal (length) and transverse (width) planes with the use
of electronic calipers and tumour volume was calculated
using the formula [(length)•(width)2]/2.
Euthanization and tissue collection
When mice reached 20 weeks (140 days) of age a vaginal
smear was taken by flushing the vagina with 30 μL of a
phosphate buffer saline solution. The solution was then
placed on a glass slide and viewed under a Nikon Eclipse
TS100 microscope for estrus cycle classification. Mice
were identified as in proestrus, estrus, metaestrus or dies-
trus cycle by cell characteristics [14]. Mice in proestrus,
estrus or metaestrus were euthanized by carbon dioxide
asphyxiation. Euthanization of mice in diestrus was de-
layed in order to control for hormonal fluctuations which
may impact cell proliferation profiles. For ethical reasons
mice which lost more than 20% of their body weight or
possessed tumours which exceeded either 17 mm in
length/width or more than 5000 mm3 in volume were
euthanized prior to the 20 week time point.
The mouse pelt, with mammary glands (MGs) and
tumors attached, was removed to allow for final tumour
volume measurements via electronic calipers, and to
remove the 4th and 5th MGs as well as all tumours. The
tumours and MGs were excised and snap-frozen in li-
quid nitrogen.
Fatty acid analysis
Lipids were extracted from the 4th and 5th MGs (n = 5
for the 0% n-3 PUFA and the 9% n-3 PUFA diets, n = 4
for the 3% n-3 PUFA diet) and tumour tissues (n = 5 for
the 0% n-3 PUFA and the 3% n-3 PUFA diets, n = 4 for
the 9% n-3 PUFA diet) via the Folch Method [32] and
separated into individual phospholipid classes by thin-
layer chromatography (TLC). In brief, the entirety of a
dissected MG adjacent to a tumour was homogenized
on ice in 0.1 M KCl, added to 2:1 CHCl3: MeOH, vor-
texed and incubated overnight at 4°C to facilitate lipid
extraction. The same technique was utilized for tumour
tissue; however, only 0.1 g of the tissue was homoge-
nized. The following day samples were centrifuged at
357 × g for 10 minutes, the chloroform layer was then
collected and dried down under a gentle stream of nitro-
gen on a warm heating block. Dried down lipids from
tumour tissues were reconstituted in chloroform to a
concentration of 10 mg/ml. Samples from MGs were
reconstituted in 200 μL of chloroform.
Lipids were spotted on H-plates (EMD Chemicals
#5721-7) which were activated by incubating the plates
in an oven for an hour at 100°C. Spotted H-plates were
then placed in a thin layer chromatography tank contain-
ing 30 ml chloroform, 9 ml methanol, 25 ml 2-propanol,
6 ml 0.25 M KCl, and 18 ml triethylamine. The plate
was then lightly sprayed with 0.1% (w/v) ANSA
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light. Bands corresponding to phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylinositol (PI)
and phosphatidylserine (PS) were collected from tumour
samples while only PC and PE bands were visible and
collected from MG samples.
Methylation was performed by adding 2 ml of hexane
and 2 ml of 14% BF3-MeOH (Sigma B1252) to the samples
and incubating them at 100°C for 90 minutes. Following
methylation, 2 ml of double distilled H2O was added to
the samples and the solution was immediately vortexed
for 30 seconds to halt methylation. Samples were cen-
trifuged for 10 minutes at 357 × g, the hexane layer
was collected and dried down under nitrogen before
reconstitution in 2 ml of hexane. Fatty acid methyl es-
ters were analyzed using a gas chromatography system
(Agilent Technologies 7890A). Fatty acid composition
was expressed as a percentage of total fatty acids.
Statistics
SAS v9.1 was utilized for all statistical analyses. A one-way
ANOVA was conducted to determine differences in final
body weights, puberty onset, tumour latency, final tumour
volume, final tumour multiplicity and fatty acid composi-
tions of tumour and MG tissues. The Kruskal-Wallis test
was performed for data that was not normally distributed.
A repeated measures analysis was utilized to detect differ-
ences in tumour volume and multiplicity between diets
over the duration of the 20 week study. A p < 0.05 was
considered significant.
Abbreviations
PUFA: Polyunsaturated fatty acids; MMTV: Mouse mammary tumour virus;
HER2: Human epidermal growth factor receptor 2; w/w: Weight/weight;
MG: Mammary gland; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid;
DPA: Docosapentaenoic acid; DHA: Docosahexaenoic acid; LA: Linoleic acid;
AA: Arachidonic acid; TLC: Thin layer chromatography;
PC: Phosphatidylcholine.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ML, SA, KP and DM were responsible for the experimental design. ML, KP
conducted the experiments, ML analyzed the data and drafted the
manuscript. ML, SA, DM revised the manuscript. WM provided the strain of
mice utilized in the experiment. All authors read and approved the final
manuscript.
Acknowledgements
Research for Dr. David W.L. Ma is funded by the Canadian Breast Cancer
Research Alliance/Canadian Institutes of Health Research operating grant
(MOP-89971) and the Canada Foundation for Innovation Leaders
Opportunity Fund with matching from the Ontario Research Fund. We
would like to thank Lyn Hillyer for her invaluable analytical expertise.
Author details
1Department of Human Health and Nutritional Sciences, University of
Guelph, Animal Science/Nutrition Building, Room 342, 491 Gordon Street,
N1G 2W1 Guelph, ON, Canada. 2Molecular Oncology Labs, McGill University,
Royal Victoria Hospital, Montreal, QC, Canada.Received: 1 May 2014 Accepted: 28 May 2014
Published: 11 June 2014
References
1. Kachuri L, De P, Ellison LF, Semenciw R: Cancer incidence, mortality and
survival trends in Canada, 1970–2007. Chronic Dis Inj Can 2013, 33:69–80.
2. Iwasaki M, Tsugane S: Risk factors for breast cancer: epidemiological
evidence from Japanese studies. Cancer Sci 2011, 102:1607–1614.
3. Saadatian-Elahi M, Norat T, Goudable J, Riboli E: Biomarkers of dietary fatty
acid intake and the risk of breast cancer: a meta-analysis. Int J Cancer
2004, 111:584–591.
4. Berquin IM, Edwards IJ, Chen YQ: Multi-targeted therapy of cancer by
omega-3 fatty acids. Cancer Lett 2008, 269:363–377.
5. Patterson RE, Flatt SW, Newman VA, Natarajan L, Rock CL, Thomson CA,
Caan BJ, Parker BA, Pierce JP: Marine fatty acid intake is associated with
breast cancer prognosis. J Nutr 2011, 141:201–206.
6. Maillard V, Bougnoux P, Ferrari P, Jourdan ML, Pinault M, Lavillonniere F,
Body G, Le FO, Chajes V: N-3 and N-6 fatty acids in breast adipose tissue
and relative risk of breast cancer in a case–control study in Tours,
France. Int J Cancer 2002, 98:78–83.
7. Pala V, Krogh V, Muti P, Chajes V, Riboli E, Micheli A, Saadatian M, Sieri S,
Berrino F: Erythrocyte membrane fatty acids and subsequent breast
cancer: a prospective Italian study. J Natl Cancer Inst 2001, 93:1088–1095.
8. Shannon J, King IB, Moshofsky R, Lampe JW, Gao DL, Ray RM, Thomas DB:
Erythrocyte fatty acids and breast cancer risk: a case–control study in
Shanghai, China. Am J Clin Nutr 2007, 85:1090–1097.
9. Iyengar NM, Hudis CA, Gucalp A: Omega-3 fatty acids for the prevention
of breast cancer: an update and state of the science. Curr Breast Cancer
Rep 2013, 5:247–254.
10. Zheng JS, Hu XJ, Zhao YM, Yang J, Li D: Intake of fish and marine n-3
polyunsaturated fatty acids and risk of breast cancer: meta-analysis of
data from 21 independent prospective cohort studies. BMJ 2013,
346:f3706.
11. Hilakivi-Clarke L, Clarke R, Onojafe I, Raygada M, Cho E, Lippman M: A
maternal diet high in n - 6 polyunsaturated fats alters mammary gland
development, puberty onset, and breast cancer risk among female rat
offspring. Proc Natl Acad Sci U S A 1997, 94:9372–9377.
12. Yee LD, Agarwal D, Rosol TJ, Lehman A, Tian M, Hatton J, Heestand J, Belury
MA, Clinton SK: The inhibition of early stages of HER-2/neu-mediated
mammary carcinogenesis by dietary n-3 PUFAs. Mol Nutr Food Res 2013,
57:320–327.
13. Ravacci GR, Brentani MM, Tortelli T Jr, Torrinhas RS, Saldanha T, Torres EA,
Waitzberg DL: Lipid raft disruption by docosahexaenoic acid induces
apoptosis in transformed human mammary luminal epithelial cells
harboring HER-2 overexpression. J Nutr Biochem 2013, 24:505–515.
14. MacLennan MB, Clarke SE, Perez K, Wood GA, Muller WJ, Kang JX, Ma DW:
Mammary tumor development is directly inhibited by lifelong n-3
polyunsaturated fatty acids. J Nutr Biochem 2013, 24:388–395.
15. Yee LD, Young DC, Rosol TJ, VanBuskirk AM, Clinton SK: Dietary (n-3)
polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in
mice independently of the PPARgamma ligand rosiglitazone. J Nutr 2005,
135:983–988.
16. Vail DM, MacEwen EG: Spontaneously occurring tumors of companion
animals as models for human cancer. Cancer Invest 2000, 18:781–792.
17. Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL,
Anders C, Devi GR, Lyerly HK, Clay TM: Long term disease-free survival and
T cell and antibody responses in women with high-risk Her2+ breast
cancer following vaccination against Her2. J Transl Med 2007, 5:42.
18. Kang KS, Wang P, Yamabe N, Fukui M, Jay T, Zhu BT: Docosahexaenoic acid
induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen
species formation and caspase 8 activation. PLoS One 2010, 5:e10296.
19. Corsetto PA, Montorfano G, Zava S, Jovenitti IE, Cremona A, Berra B, Rizzo
AM: Effects of n-3 PUFAs on breast cancer cells through their
incorporation in plasma membrane. Lipids Health Dis 2011, 10:73.
20. Ma DW, Seo J, Switzer KC, Fan YY, McMurray DN, Lupton JR, Chapkin RS:
n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid
research. J Nutr Biochem 2004, 15:700–706.
21. Ma DW: Lipid mediators in membrane rafts are important determinants
of human health and disease. Appl Physiol Nutr Metab 2007, 32:341–350.
22. Weisburger JH: Dietary fat and risk of chronic disease: mechanistic
insights from experimental studies. J Am Diet Assoc 1997, 97:S16–S23.
Leslie et al. Lipids in Health and Disease 2014, 13:96 Page 8 of 8
http://www.lipidworld.com/content/13/1/9623. Maclennan M, Ma DW: Role of dietary fatty acids in mammary gland
development and breast cancer. Breast Cancer Res 2010, 12:211.
24. Kris-Etherton PM, Innis S, Ammerican DA, Dietitians of Canada: Position of
the American Dietetic Association and Dietitians of Canada: dietary fatty
acids. J Am Diet Assoc 2007, 107:1599–1611.
25. Yee LD, Lester JL, Cole RM, Richardson JR, Hsu JC, Li Y, Lehman A, Belury
MA, Clinton SK: Omega-3 fatty acid supplements in women at high risk
of breast cancer have dose-dependent effects on breast adipose tissue
fatty acid composition. Am J Clin Nutr 2010, 91:1185–1194.
26. Turner N, Mitchell TW, Else PL, Hulbert AJ: The omega-3 and omega-6 fats
in meals: a proposal for a simple new label. Nutrition 2011, 27:719–726.
27. Liu YE, Pu W, Wang J, Kang JX, Shi YE: Activation of Stat5 and induction of
a pregnancy-like mammary gland differentiation by eicosapentaenoic
and docosapentaenoic omega-3 fatty acids. FEBS J 2007, 274:3351–3362.
28. Kremmyda LS, Tvrzicka E, Stankova B, Zak A: Fatty acids as biocompounds:
their role in human metabolism, health and disease: a review. part 2:
fatty acid physiological roles and applications in human health and
disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011,
155:195–218.
29. Park SK, Kim Y, Kang D, Jung EJ, Yoo KY: Risk factors and control strategies
for the rapidly rising rate of breast cancer in Korea. J Breast Cancer 2011,
14:79–87.
30. Biro FM, Greenspan LC, Galvez MP, Pinney SM, Teitelbaum S, Windham GC,
Deardorff J, Herrick RL, Succop PA, Hiatt RA, Kushi LH, Wolff MS: Onset of
breast development in a longitudinal cohort. Pediatrics 2013,
132:1019–1027.
31. Biro FM, Deardorff J: Identifying opportunities for cancer prevention
during preadolescence and adolescence: puberty as a window of
susceptibility. J Adolesc Health 2013, 52:S15–S20.
32. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and
purification of total lipids from animal tissues. J Biol Chem 1957,
226:497–509.
doi:10.1186/1476-511X-13-96
Cite this article as: Leslie et al.: Mammary tumour development is
dose-dependently inhibited by n-3 polyunsaturated fatty acids in the
MMTV-neu(ndl)-YD5 transgenic mouse model. Lipids in Health and
Disease 2014 13:96.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
